Clin Pharmacol Ther. May 2013; 93(5): 402–408.
© 2013 American Society of Clinical Pharmacology and Therapeutics
Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants
1Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA
2Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands
3Department of Genetics, Stanford University, Stanford, California, USA
4Division of Clinical and Translational Research, Department of Anesthesiology, Washington University in St. Louis, St. Louis, Missouri, USA
5Department of Clinical, Social and Administrative Sciences, College of Pharmacy, Ann Arbor, Michigan, USA
6Department of Psychiatry, School of Medicine, University of Michigan, Ann Arbor, Michigan, USA
7Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA
8Neurogenetics Section, Centre for Addiction and Mental Health, and Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
9Division of Pediatric Pharmacology and Medical Toxicology, Children's Mercy Hospital & Clinics, Kansas City, Missouri, USA
10Division of Research, Federal Institute for Drugs and Medical Devices, Bonn, Germany
Received October 1, 2012; Accepted December 27, 2012.